# Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

> **NCT04034238** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Neoplasms With Mesothelin Expression
- Epithelioid Mesothelioma
- Cholangiocarcinoma, Extrahepatic
- Adenocarcinoma, Pancreatic

## Interventions

- **DRUG:** LMB-100
- **DRUG:** Tofacitinib
- **DEVICE:** Mesothelin Expression

## Key facts

- **NCT ID:** NCT04034238
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-29
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-11-19
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034238, "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04034238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*